Skip to main content

ramipril

 

Following a limited submission

AWMSG advice

Status: Recommended

Ramipril oral solution is recommended as an option for use within NHS Wales for:

  • Treatment of hypertension.
  • Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:
    • manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease);
    • diabetes with at least one cardiovascular risk factor.
  • Treatment of renal disease:
    • incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria;
    • manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor;
    • manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.
  • Treatment of symptomatic heart failure.
  • Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.
 Final Recommendation: ramipril oral solution 1639 (PDF, 360Kb)
 Appraisal Report: ramipril oral solution 1639 (PDF, 223Kb)

Medicine details

Medicine name ramipril
Formulation 2.5 mg/5 ml oral solution
Reference number 1639
Indication
  • Treatment of hypertension.
  • Reduction of cardiovascular morbidity and mortality in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or diabetes with at least one cardiovascular risk factor.
  • Treatment of renal disease in patients with incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria or in patients with manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor or in patients with manifest glomerular non diabetic nephropathy as defined by macroproteinuria 3 g/day.
  • Treatment of symptomatic heart failure.
  • Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction
Company Rosemont Pharmaceuticals Ltd
BNF chapter Cardiovascular system
Submission type Limited
Status Recommended
Advice number 2612
NMG meeting date 05/09/2012
AWMSG meeting date 17/10/2012
Ratification by Welsh Government 09/11/2012
Date of issue 13/11/2012
Date of last review November 2022
Further information

This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations

Scrutiny Panel meeting date useMuraDefault
LOWMAG meeting date useMuraDefault
OWMAG meeting date useMuraDefault
Follow AWTTC: